RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma
RPL29 downregulation following 2 Gy radiotherapy correlates with improved prognosis in MM, highlighting its potential as a clinically relevant prognostic biomarker. These findings provide new insights into MM biology and establish a foundation for targeted therapeutic strategies involving RPL29 and related pathways.
Authors
- Yanping Ma (ORCID: https://orcid.org/0000-0001-5421-5822)
- Hongxiu Liu (ORCID: https://orcid.org/0000-0001-9081-9471)
- Zhihua Li (ORCID: https://orcid.org/0000-0001-6564-6927)
- Yihua Wang (ORCID: https://orcid.org/0000-0001-5561-0648)
- Jia Qi (ORCID: https://orcid.org/0000-0003-4099-2617)
Institutions
- Shanxi Medical University (CN)
- Second Hospital of Shanxi Medical University (CN)
- Taiyuan Central Hospital (CN)
- Fourth People's Hospital of Taiyuan (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1186/s12957-025-04038-z
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00